Genmab — August 2018
-
-
From Syros Pharmaceuticals - Earnings Call Transcript : Over the course of the next several months, we plan to report initial, data from our Phase 2 trial of 1425 in combination with azacitidine and with daratumumab in AML and MDS patients. https://seekingalpha.com/article/4198857-syros-pharmaceuticals-syrs-ceo-nancy-simonian-q2-2018-results-earnings-call-transcript?part=single
-
-
Godt nok svært at ikke at elske den mand, når man er pro Genmab
-
Jeg synes da ikke han hyper den specielt meget - han har jo ret i det han siger og holder egentlig blot fast i at Darzalex i MM med meget stor sandsynlighed er mere værd alene end der tilskrives nu - det er af helt samme grund jeg holder fast. Alt hvad der kommer derudover er bonus
-
Hype eller ej det er ikke noget der rykker kursen op
-
Du har ret i, at det nok formentlig er minimalt hvad han kan påvirke kursen. Dog synes jeg aldrig det er en dårlig ting, at han i hvert fald gør informationen mere tilgængelig for den mere normale private investorer, end dem der befinder sig herinde.
-
Florian flytter altså ikke kursen i Genmab med sine indlæg i medierne.
-
mon ikke at han allerede ligger inde med en ret stor potion
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind